Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; Implications for prevention of stroke and AD

Biochemical and Biophysical Research Communications

Volumn 402, Issue 2, 2010, Pages 367-372

  Famer, D ^a   Wahlund, L O ^a   Crisby, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Apolipoprotein E; Interleukin 6; Microglia; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN E; C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 6; ROSUVASTATIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; WILD TYPE;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; DIET; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MICE; MICE, KNOCKOUT; MICROGLIA; PYRIMIDINES; STROKE; SULFONAMIDES;

MUS;

EID: 78149468901     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.035     Document Type: Article

References (45)

1. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:741-749.
2. Weinstein J.R., Koerner I.P., Möller T. Microglia in ischemic brain injury. Future Neurol. 2010, 5:227-246.
3. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Arauz D.E. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1989, 86:7611-7615.
4. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991, 285:111-114.
5. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C.F. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 1993, 7:75-83.
6. Ravaglia G., Paola F., Maioli F., Martelli M., Montesi F., Bastagli L., Bianchin M., Chiappelli M., Tumini E., Bolondi L., Licastro F. Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. Exp. Gerontol. 2006, 41:85-92.
7. Taga T., Kishimoto T.E. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol 1997, 15:797-819.
8. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA 1993, 90:10061-10065.
9. Gruol D.L., Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 1997, 15:307-339.
10. Teunissen C.E., van Boxtel M.P.J., Bosma H., Bosmans E., Delanghe J., de Bruijn C., Wauters A., Maes M., Jolles J., Steinbusch H.W.M., de Vente J. Inflammation markers in relation to cognition in a healthy aging population. J. Neuroimmunol. 2003, 134:142-150.
11. Weaver J.D., Huang M.H., Albert M., Harris T.B., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59:371-378.
12. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., Launer L., Kuller L., Rubin S., Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
13. Everett B.M., Kurth M., Burning J.E., Ridker P.M. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J. Am. Coll. Cardiol. 2006, 48:2235-2242.
14. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2865-2867.
15. Fagan A.M., Holtzman D.M., Munson G., Mathur T., Schneider D., Chang L.K., Getz G.S., Reardon C.A., Lukens J., Shah J.A., LaDu M.J. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J. Biol. Chem. 1999, 274(42):30001-30007.
16. Hayashi T., Kamada H., Jin G., Deguchi K., Nagatani S., Sehara Y., Zhang H., Nagano I., Shoji M., Abe K. Different expression of low density lipoprotein receptor and ApoE between young adult and old rat brains after ischemia. Neurol. Res. 2006, 28:822-825.
17. Brown C.M., Wright E., Colton C.A., Sullivan P.M., Laskowitz D.T., Vitek M.P. Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic. Biol. Med. 2002, 32:1071-1075.
18. Saunders A.M., Strittmatter W.J., Schmechel D.E., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Albersts M.J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
19. Schram M.T., Euser S.M., de Craen A.J., Witteman J.C., Frolich M., Hofman A., Jolles J., Breteler M.M., Westendorp R.G. Systemic markers of inflammation and cognitive decline in old age. J. Am. Geriatr. Soc. 2007, 55:708-716.
20. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
21. Crisby M., Rahman S.M.A., Sylven C., Winblad B., Schultzberg M. Effects of high cholesterol on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke. Neurosci. Lett. 2004, 369:87-92.
22. Rahman S.M.A., Van Dam A.M., Schultzberg M., Crisby M. High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice. J. Neuroimmunol. 2005, 169:59-67.
23. Masse I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C., Pasquier F. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:1611-1613.
24. Famer D., Crisby M. Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Neurosci. Lett. 2004, 371:209-214.
25. Lindberg C., Crisby M., Winblad B., Schultzberg M. Effects of statins on microglia. J. Neurosci. Res. 2005, 82:10-19.
26. Famer D., Crisby M. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Neurosci. Lett. 2007, 419:68-73.
27. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2004, Academic Press, San Diego, USA. second ed.
28. Gordon M.N. Microglia and immune activation in Alzheimer's disease. J. Fla. Med. Assoc. 1993, 80:267-270.
29. Rozovsky I., Finch C.E., Morgan T.E. Age-related activation of microglia and astrocytes: in vitro studies show persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol. Aging 1998, 19:97-103.
30. Crisby M., Carlson L.A., Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2002, 16:131-136.
31. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore M.K., Tsuang D., van Belle G., McCormick W., D Bowen J., Teri L., Schellenberg G.D., Larson E.B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628.
32. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry. 2005, 62:217-224.
33. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 2002, 59:223-227.
34. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
35. Kleemann R., Princen H.M., Emeis J.J., Jukema J.W., Fontijn R.D., Horrevoets A.J., Kooistra T., Havekes L.M. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003, 108:1368-1374.
36. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C., Breteler M.M. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch. Neurol. 2004, 61:668-672.
37. Ridker P.M., MacFadyen J., Libby P., Glynn R.J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 2010, 204-209.
38. Li B., Mahmood A., Lu D., Wu H., Xiong Y., Qu C., Chopp M. Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 2009, 65:179-186.
39. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 2002, 45:47-154.
40. Libermann T.A., Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell Biol. 1990, 10:2327-2334.
41. Torreilles F., Salman-Tabcheh S., Guerin M., Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res. Rev. 1999, 30:153-163.
42. Otto A., Fontaine J., Tschirart E., Fontaine D., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of NAD(P)H oxidase pathway. Br. J. Pharmacol. 2006, 148:544-552.
43. Whaley-Connell A.T., Morris E.M., Rehmer N., Yaghoubian J.C., Wei Y., Hayden M.R., Habibi J., Stump C.S., Sowers J.R. Albumin activation of NAD(P)H oxidase activity is mediated via RaC1 in proximal tubule cells. Am. J. Nephrol. 2007, 27:15-23.
44. Cordle A., Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J. Neurosci. 2005, 25:299-307.
45. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol. Chem. 2005, 280:34202-34209.